Geno
|
Mag
|
Summary
|
(C;G)
|
5.1
|
Multiple Endocrine Neoplasia IIA
|
(G;G)
|
0
|
common in clinvar
|
(G;T)
|
5.1
|
Multiple Endocrine Neoplasia IIA
|
ClinVar
|
Risk
|
rs79658334(A;A) rs79658334(C;C) rs79658334(T;T) |
Alt
|
rs79658334(A;A) rs79658334(C;C) rs79658334(T;T) |
Reference
|
Rs79658334(G;G) |
Significance |
Pathogenic |
Disease |
Multiple endocrine neoplasia MEN2A and FMTC Multiple endocrine neoplasia not provided Hereditary cancer-predisposing syndrome Familial medullary thyroid carcinoma MEN2 phenotype: Unclassified Multiple endocrine neoplasia Multiple endocrine neoplasia Medullary thyroid carcinoma Multiple endocrine neoplasia Multiple endocrine neoplasia |
Variation | info |
---|
Gene |
RET |
CLNDBN |
Multiple endocrine neoplasia, type 2b MEN2A and FMTC Multiple endocrine neoplasia, type 2 not provided Hereditary cancer-predisposing syndrome Familial medullary thyroid carcinoma MEN2 phenotype: Unclassified Multiple endocrine neoplasia, type 1 Multiple endocrine neoplasia, type 2a Medullary thyroid carcinoma Multiple endocrine neoplasia, type 4 Multiple endocrine neoplasia |
Reversed |
0 |
HGVS |
NC_000010.10:g.43614996G>A; NC_000010.10:g.43614996G>C; NC_000010.10:g.43614996G>T |
CLNSRC |
OMIM Allelic Variant UniProtKB (protein) |
CLNACC |
RCV000014972.26, RCV000021852.1, RCV000148773.3, RCV000182584.4, RCV000210181.1, RCV000268357.1, RCV000021853.1, RCV000419916.1, RCV000425568.1, RCV000426266.1, RCV000436948.1, RCV000437130.1, RCV000479688.1, RCV000014973.26, RCV000021854.1, RCV000354366.1, RCV000487450.1, |
[PMID 11589684] Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population.
[PMID 12694233] Segregation of the V804L mutation and S836S polymorphism of exon 14 of the RET gene in an extended kindred with familial medullary thyroid cancer.
[PMID 15741265] Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients.